ClinicalTrials.gg
Active, not recruitingNCT07024407ANDECA-HOUpdated Nov 5, 2026

A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.

A Phase 1/2 interventional study of Andecaliximab in Heterotopic Ossification (HO), sponsored by Ashibio Inc. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Ashibio Inc · Phase 1/2, Interventional, and Prevention

Updated Nov 5, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Ossification, Heterotopic with a site in United States — 3 open to participants now, 6 under way, 2 of them phase 3. Ossification, Heterotopic · United States.

Planned enrollment
10th of 13
10 · median 63
Started
2025
with 1 other
Phase 1/2
Only one
of the 18
Registered
18th of 18
by date
Lead sponsor
2 of 18
Ashibio Inc

Among the 18 studies in Ossification, Heterotopic with a site in United States, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 1/2, and was the 18th registered.

Ossification, Heterotopic

38 studies on the registry are indexed under Ossification, Heterotopic; 7 are open to participants now.

Browse Ossification, Heterotopic studies →

Open to participants now

3 of the 18 studies in Ossification, Heterotopic with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Ossification, Heterotopic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Ossification, Heterotopic with a site in United States, or all of them as a file.
02

Study summary

This is an open-label study of andecaliximab in participants at risk of developing bone where bone should not be, such as in muscle, tendons, and other soft tissues following traumatic spinal cord injury. The goal of this study is to assess the safety of andecaliximab, how much drug is in the body over time (pharmacokinetics/PK), and how it affects the body (pharmacodynamics/PD) in participants who have had a recent traumatic spinal cord injury.

Read the detailed description

Safety: To evaluate the safety profile of andecaliximab in participants with spinal cord injurySCI at risk for Heterotopic Ossification.

PK: To describe the PK profile of andecaliximab in all participants.

Secondary Objective:

PD: To describe the PD profile of andecaliximab in all participants.

03

Conditions studied

  • Heterotopic Ossification (HO)

Keywords

  • Heterotopic Ossification
  • traumatic spinal cord injury
04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 89 years.
  2. History of traumatic SCI that occurred a minimum of 10 days prior to first study dose.
  3. No significant HO identified by CT as defined in the Imaging Charter and meeting one of the following sets of criteria based on TPBS at end of screening:

The Inflammatory Group: Inflammation consistent with developing HO The Early HO Group: The third phase on TPBS shows minimal extraskeletal uptake

The Prophylactic High-Risk Group: No findings consistent with increased risk of HO but meets all of the following clinical risk factors for HO:

  1. Within 1 month of injury AND
  2. AIS Grade A AND
  3. Male AND
  4. Age 18 to 45 years 4. Participant or legal representative able and willing to give and to adhere to the visits schedule and study procedures.

5. Able to understand, undergo, and perform all protocol related procedures. 6. Agrees to provide access to all relevant current and historical medical records

Exclusion criteria

Exclusion Criteria:

  1. History of:

    1. Known monogenic disorder associated with HO.
    2. Bone or mineral disorder unrelated to HO or SCI.
    3. (within the past 5 years). Untreated active infection at the time of enrollment Uncontrolled hypoparathyroidism or hyperparathyroidism Uncontrolled hyperthyroidism, based on participant report or chart review. Hyperthyroidism is defined by the presence of both a TSH level below the normal range and elevated T4.
    4. Current infection with COVID-19 or COVID-19 infection within 1 month of Study Day 1 if treated with nirmatrelvir/ritonavir or other COVID-19 antiviral with a risk of rebound. (If a potential participant is experiencing mild COVID-19-like symptoms, they should wait until they are asymptomatic and/or rule out COVID-19 infection by local COVID-19 PCR testing prior to on-site screening.) Asymptomatic patients are not required to undergo COVID-19 testing.
    5. COVID-19 vaccine within 1 month of Study Day 1.
  2. Use of the following medication:

    1. Current or chronic use of tetracycline drugs
    2. Activated (1,25-OH) vitamin D (vitamin D2 and D3 allowed), phosphate or calcium supplements within 1 week of Study Day 1
    3. Treatment with another product within 5 half lives of last dose at the time of Study Day 1 or one month, whichever is longer.
  3. History of allergy or to andecaliximab or its .
  4. Any of the following abnormalities detected on laboratory evaluation prior to Study Day 1:

    1. 25-OH vitamin D \<16 ng/mL (\<39.94 nmol/L).
    2. Current albumin corrected serum calcium level \<8.0 mg/dL or >11 mg/dL, or requiring treatment with IV fluids and/or bisphosphonates for hypercalcemia at time of enrollment.
    3. Impaired renal function. (estimated [eGFR] \< 40 mL/min/1.73m2)
    4. Hepatic panel [ (AST), alanine aminotransferase (ALT), total , direct bilirubin, lactate dehydrogenase (LDH)] >3 × for ageHemoglobin \<9.5 g/dL (\<5.9 mmol/L).
    5. (ANC) \<1,500 mm3(\<1.5 × 109/L).
    6. \<75,000/μL (\<75 × 109/L).
  5. Breastfeeding.
  6. Pregnancy, planned pregnancy, or unwillingness to use acceptable during the study and for 90 days after the last dose.
  7. Simultaneous participation in another interventional clinical trial.
  8. Any other significant medical condition or disability or biochemical or hematologic abnormalities, that in the opinion of the Investigator would expose the participant to undue risk, prevent the conduct of study procedures, or confound the study results.
  9. Employees of the Sponsor, study site, or CRO involved in the conduct of the study or immediate family members thereof.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Andecaliximab

    All participants will receive andecaliximab whether at risk for developing HO or at risk for worsening of early HO.

    Drug: Andecaliximab

Interventions

  • Participants will receive weekly subcutaneous injections of andecaliximab during inpatient hospitalization, clinic visit, or self-administration if discharged from the hospital

06

What researchers measure

Primary outcomes

  1. To evaluate the safety of andecaliximab in participants with SCI at risk for HO

    Incidence and severity of all serious adverse events (SAEs) and all treatment-emergent adverse events (TEAEs)

    Time frame: From signing of the informed consent form until the end of the Safety Follow-up Period (4 weeks after week 9 or Early Termination)

  2. To describe the PK profile of andecaliximab in all participants

    PK parameters (area under the time-concentration curve \[AUC\], maximum concentration \[Cmax\],

    Time frame: From baseline (Week 1) through Week 9 or Early Termination

  3. To describe the PK profile of andecaliximab in all participants

    PK concentration at steady state \[Ctrough\]) describing the profile of andecaliximab

    Time frame: From baseline (Week 1) through Week 9 or Early Termination

Secondary outcomes

  1. To describe the PD profile of andecaliximab in all participants

    Andecaliximab MMP9 target coverage in plasma over time

    Time frame: From baseline (Week 1) through Week 9 or Early Termination

Other outcomes

  1. Exploratory: To evaluate the efficacy of andecaliximab to inhibit new HO or continued development of HO in all participants

    Radiographic studies to determine percent of participants with new HO lesion; and percent of participants with critical new HO volume

    Time frame: From baseline (Week 1) to Week 9

  2. To evaluate the response to adecaliximab in participant function

    Changes in passive range of motion testing (PROM)/active range of motion testing (AROM)

    Time frame: From baseline (Week 1) to Week 9

  3. To evaluate the response to adecaliximab in participant function

    Changes in International Standard for Neurological Classification of Spinal Cord Injury (ISNCSCI)

    Time frame: From baseline (Week 1) to Week 9

  4. To evaluate the response to andecaliximab in participant pain

    Changes in International Spinal Cord Society (ISCOS) Spinal Cord Injury Pain Classification

    Time frame: From baseline (Week 1) to Week 9

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2025 (actual). Primary completion is estimated for Dec 2028, 43 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2025 → Dec 2028 and completion Jan 2026 → Jan 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
Jun 17, 2025
StartActual
May 14, 2025
Primary completionEst.
Dec 2028was Dec 2025
CompletionEst.
Jan 2029was Jan 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 5, 2026
Primary completion
Dec 2025→Dec 2028
Nov 5, 2026
Study completion
Jan 2026→Jan 2029
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 2025→Dec 2028
    Study completion Jan 2026→Jan 2029
    + 5 other changes: index terms, verification date, criteria formatting, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07024407
Lead sponsor
Ashibio Inc
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
May 14, 2025
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

Andrew Park, MD
principal investigator · Craig Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andecaliximab

Start the discussion